Collaboration is a powerful antidote
To maintain the steady flow of innovative therapeutics and diagnostic tools, there is a need for research teams to identify sources of appropriate knowledge and expertise outside their own organisations and build collaborative partnerships.
“Collaboration can make all the difference to patients and their loved ones, and we work together to make it happen. Collaboration is a powerful antidote to the challenges and barriers that face all of us in the pursuit of curing illness. Now, more than ever, we need collaboration to tackle the huge challenges of finding new cures,” said Carol Bewick.
“Five years ago, few charities collaborated outside of academia; their independence was something they were proud of. Keeping others at arm’s length was a way to protect themselves, but in reality a storm was brewing. Charities needed to start thinking more about what impact their research efforts were having on the people they served.
They had to question whether they could show much progress in delivering new treatments and therapies so desperately needed,” recalls Bewick.
Partnerships must focus on patients
In 2014, the AMRC took the bold step of producing a guide to help charities begin to collaborate with industry. “We are now seeing the seeds of change with a plethora of new partnerships. In this year alone, we have seen several promising partnerships formed, including those stimulated by LifeArc. These partnerships are driven by the need to put patients first, to truly understand the impact of a disease or condition and to focus on what really matters.” said Bewick. “Patients are now active participants and partners in research.”
At LifeArc we believe that collaborations with charities are critical. We need to understand that the medicines and diagnostics we are developing will actually benefit patients’ lives and our charity partners help us access that insight. The ‘Patient First’ approach means the patient’s voice is heard in all collaborations.All Case Studies